{"id":"W4410158978","doi":"10.1182/blood.2025028357","title":"Menin inhibition with revumenib for <i>NPM1</i>-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study","year":2025,"lang":"en","type":"article","venue":"Blood","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Swedish Orphan Biovitrum; Daiichi Sankyo Europe; National Cancer Institute; Foghorn Therapeutics; Gilead Sciences; Servier; Astellas Pharma; Genentech; Y-mAbs Therapeutics; MacroGenics; Syndax Pharmaceuticals; Pfizer; Incyte; Agios Pharmaceuticals; American Society of Pediatric Hematology/Oncology; Astex Pharmaceuticals; Jazz Pharmaceuticals; Alexion Pharmaceuticals; Kite Pharma; Sanofi; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; GlaxoSmithKline","keywords":"Medicine; Internal medicine; Discontinuation; Myeloid leukemia; Tolerability; Population; Adverse effect; Refractory (planetary science); Phases of clinical research; Oncology; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000902392,0.0003644105,0.0005638336,0.0002707249,0.0003961172,0.00007482873,0.0002880348,0.0002085972,0.00009770668],"category_scores_gemma":[0.0002888872,0.0002077493,0.0001533275,0.0009990117,0.0001769665,0.0001703754,0.0001684736,0.0008145853,0.00004014464],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008754378,"about_ca_system_score_gemma":0.001918806,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001160869,"about_ca_topic_score_gemma":0.0001223464,"domain_scores_codex":[0.997272,0.0002094168,0.0005383121,0.0006810669,0.0006544634,0.0006447276],"domain_scores_gemma":[0.9978902,0.0004596567,0.0001727949,0.0009350405,0.0003682282,0.000174078],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.06816211,0.01560526,0.01506994,0.00169164,0.02201762,0.00573178,0.008530512,0.00004194984,0.5129881,0.0008459885,0.3286912,0.02062394],"study_design_scores_gemma":[0.3089719,0.0406214,0.01992737,0.00279314,0.02163113,0.001316702,0.01564103,0.0007605756,0.4474655,0.0005450999,0.1382752,0.002050909],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855791,0.000328903,0.0004290337,0.003886882,0.0001445383,0.005687356,0.00005631781,0.0002521399,0.003635714],"genre_scores_gemma":[0.9640224,0.0001969961,0.001799275,0.001513208,0.0002805967,0.00158004,0.0002003161,0.00009723446,0.03030991],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2408098,"threshold_uncertainty_score":0.8471771,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0174446013702846,"score_gpt":0.300949740871285,"score_spread":0.2835051395010004,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}